Search results for "Second Primary"

showing 10 items of 61 documents

CD28, a marker associated with tumoral expansion in multiple myeloma

1998

International audience; CD28 expression was thoroughly investigated on plasma cells of monoclonal gammopathy of undetermined significance, multiple myeloma (MM), and human myeloma cell lines. CD28+ plasma cells were detected in 19% of 31 monoclonal gammopathy of undetermined significance, 41% of 116 MM, and 100% of 13 human myeloma cell lines. CD28+ myeloma cells were detected in 21 of 79 (26%) MM cases at diagnosis, 13 of 22 (59%) at medullary relapse (P < 0.009), and 14 of 15 (93%) at extramedullary relapse (P = 0.05), including 10 of 10 (100%) secondary plasma cell leukemias (P = 0.05). Serial studies in individual patients confirmed the emergence of CD28+ myeloma cells with tumoral expa…

Membrane GlycoproteinsParaproteinemiasNeoplasms Second Primarychemical and pharmacologic phenomenahemic and immune systemsCD56 AntigenCell LineLeukemia Plasma CellCD28 AntigensAntigens CDBone MarrowPredictive Value of TestsRecurrence[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]hemic and lymphatic diseasesB7-1 AntigenBiomarkers TumorDisease ProgressionTumor Cells CulturedHumansB7-2 AntigenTreatment Failure[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]Multiple Myeloma[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]
researchProduct

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

2022

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 A…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentColorectal cancercancer survivorPopulationBreast NeoplasmsSettore MED/42 - Igiene Generale E ApplicataProstate cancerBreast cancerRisk FactorsInternal medicineNeoplasmsfollow-upMedicineHumanscancer survivorsCumulative incidenceadolescentseducationLung cancerRetrospective Studieseducation.field_of_studyBladder cancerbusiness.industryIncidenceCancerregistriesNeoplasms Second Primarymedicine.diseasehumanitiesregistrieOncologyadolescents cancer survivors follow-up registries young adultyoung adultFemalebusiness
researchProduct

The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of …

2008

The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The …

OncologyAdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsSettore MED/06 - Oncologia MedicaPopulationDermatologyCohort StudiesRisk FactorsInternal medicineEpidemiology of cancerMedicineHumansRegistriesSurvivorseducationMelanomaAgedAged 80 and overeducation.field_of_studybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseasehumanitiesConfidence intervalcutaneous melanomacancerOncologyItalyCohortCutaneous melanomaFemalesecond cancer - survivors - malignant melanomabusinessCohort studyFollow-Up StudiesMelanoma research
researchProduct

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

2015

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of diseases that are known to carry a considerable risk of second primary cancer (SPC). However, little attention has been paid to SPC risk assessment according to NHL subtypes. Data from 10 French population-based cancer registries were used to establish a cohort of 7546 patients with a first diagnosis of NHL (eight subtypes) between 1989 and 2004. Standardized incidence ratios (SIRs) of metachronous SPC were estimated. Among the 7546 patients diagnosed with a NHL, the overall SPC risk was 25% higher than that in the reference population (SIR = 1.25, 95% confidence interval 1.15–1.36). In univariate analysis, the SPC risk differed…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyanimal structuresMultivariate analysisAdolescentPopulationRisk AssessmentCohort StudiesYoung Adultimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiologymedicineHumansRegistrieseducationChildAgedAged 80 and overUnivariate analysiseducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinfungiAge FactorsInfant NewbornCancerInfantNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseOncologyChild PreschoolPopulation SurveillanceCohortImmunologyFemaleFranceRisk assessmentbusinessFollow-Up StudiesLeukemialymphoma
researchProduct

Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of th…

2000

We determined prospectively the incidence of chromosomal abnormalities in patients with high-risk breast cancer (HRBC) after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), and correlated the cytogenetic abnormalities with the development of post-transplant myelodysplastic syndrome or acute myeloid leukemia (MDS/AML). From 1990 to 1999, 229 women with HRBC underwent ASCT. Cytogenetic analysis of bone marrow (BM) cells was performed 12–59 months after ASCT in 60 consecutive women uniformly treated with six courses of FAC/FEC followed by HDCT and ASCT. With a median follow-up of 36 months after ASCT, there were no cases of MDS/AML among the 229 patients. In the …

OncologyAdultmedicine.medical_specialtyPathologyPopulationAneuploidyBreast NeoplasmsTransplantation AutologousBreast cancerAutologous stem-cell transplantationBone MarrowPredictive Value of Testshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdjuvant therapyMedicineHumanseducationCyclophosphamideEpirubicinNeoplasm StagingChromosome AberrationsTransplantationeducation.field_of_studyLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyTransplantationPostmenopausemedicine.anatomical_structurePremenopauseChemotherapy AdjuvantDoxorubicinMyelodysplastic SyndromesFemaleBone marrowFluorouracilbusinessBone marrow transplantation
researchProduct

Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).

2020

e23518 Background: In patients with GIST, literature reports a risk of second primary tumors between 4.5% and 33% with different distribution in the worldwide. The network of 7 italian EURACAN centers has collected clinical and molecular features of GIST patients with second primary tumors. Methods: We reviewed the clinical characteristics of 201 patients with GIST and second primary tumors in order to evaluate association between risk of dead and each possible factor, using Kaplan meier curve, log-rank test and Cox model for Hazard Ratio and it’s interval Confidence 95% estimation. Furthermore, NGS analysis ( 56 gene onco panel) in 72 patients with GIST was performed. Results: On the basi…

OncologyCancer Researchmedicine.medical_specialtyGiSTbusiness.industryGIST - Gastrointestinal stromal tumorSecond primary cancerdigestive system diseasesOncologyInternal medicinemedicineIn patientbusinessneoplasmsJournal of Clinical Oncology
researchProduct

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

2007

Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a malignancy occurring after exposure to chemotherapy and/or radiotherapy. Polymorphisms involved in chemotherapy/radiotherapy response genes could be related to an increased risk of developing this neoplasia. We have studied 11 polymorphisms in genes of drug detoxification pathways (NQO1, glutathione S-transferase pi) and DNA repair xeroderma pigmentosum, complementation group (3) (XPC(3), X-ray repair cross complementing protein (1)), Nijmegen breakage syndrome (1), excision repair cross-complementing rodent repair deficiency, complementation group (5) and X-ray repair cross complementing protein (3) and in the methy…

OncologyCancer Researchmedicine.medical_specialtyXeroderma pigmentosumAntineoplastic AgentsBreast NeoplasmsSingle-nucleotide polymorphismPolymorphism Single NucleotideBreast cancerRisk Factorshemic and lymphatic diseasesInternal medicinemedicineHumansMethylenetetrahydrofolate Reductase (NADPH2)Leukemiabiologybusiness.industryHaplotypeMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseHaplotypesOncologyCase-Control StudiesHematologic NeoplasmsMethylenetetrahydrofolate reductaseImmunologybiology.proteinbusinessNijmegen breakage syndromeNucleotide excision repairLeukemia
researchProduct

The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up.

2007

The aim of this study was to calculate the risk of metachronous colorectal cancers, to specify their characteristics and potential risk factors in a well-defined French population over a 27-year period.The 10,801 patients who had colorectal cancers totalled 61,879 person-years of follow-up. The actuarial method was used to obtain crude metachronous colorectal cancer rates. Standardised incidence ratios (SIRs) were calculated.The cumulative rate of metachronous colorectal cancer was 1.8% at 5 years, 3.4% at 10 years and 7.2% at 20 years. The incidence of metachronous colorectal cancer following a first colorectal cancer was higher than expected (SIR: 1.5 [1.3-1.7] p0.001). It remained greate…

OncologyMaleCancer Researchmedicine.medical_specialtyColorectal cancerPopulationColonoscopyGastroenterologyInternal medicineEpidemiologymedicineHumanseducationAgededucation.field_of_studymedicine.diagnostic_testPotential riskbusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryColonoscopymedicine.diseaseOncologyMulticenter studyFemaleFrancebusinessColorectal NeoplasmsEpidemiologic MethodsEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up.

2012

In unsparing efforts to find the hidden primaries, second primary cancers (SPCs) unrelated to cancer of unknown primary (CUP) are found. The detection rates of SPCs after CUP can be considered as measures for the effectiveness of modern diagnostic techniques in finding tumors. We aimed to compare the rates of specific SPCs found after the work-up of CUP and the more sign/symptom-directed diagnostic approaches applied after any other cancer. The number of CUP patients identified in the nationwide Swedish database and nine German cancer registries was 24 641 from 1997 through 2006, and rate ratios (RRs) for SPCs were recorded in two follow-up periods. The detection rate of SPCs immediately af…

OncologyMaleCancer Researchmedicine.medical_specialtyDatabases FactualEpidemiologySecond Primary CancersProstateInternal medicineGermanymedicineHumansRegistriesAgedAged 80 and overSwedenUrinary bladderLungbusiness.industryPublic Health Environmental and Occupational HealthCancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseWork-upLymphomaSurgerymedicine.anatomical_structureTreatment OutcomeOncologyCancer of unknown primaryNeoplasms Unknown PrimaryFemalebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.

2012

Department of Otorhinolaryngology, Johannes Gutenberg-University, Mainz, GermanyINTRODUCTION: Functional polymorphisms (SNPs) ofthe vascular endothelial growth factor (VEGF) are asso-ciated with the incidence of oral squamous cell carcinoma(OSCC). An impact of VEGF-SNPs on prognosis of OSCCpatients seems possible. Therefore, correlations betweenprognostic parameters of OSCC patients and five VEGF-SNPs were determined.MATERIALS AND METHODS: In a retrospective long-term study, in 113 OSCC patients that underwentcurative resections, five VEGF-SNPs ( 1154 G/A,+405 G/C, +936 C/T, 2578 C/A, and 460 C/T) wereanalyzed. Associations between SNPs and prognosis(incidence of local recurrent disease, seco…

OncologyMaleVascular Endothelial Growth Factor ACancer ResearchAdenosinechemistry.chemical_compoundGene FrequencyPolymorphism (computer science)Longitudinal StudiesAged 80 and overIncidence (epidemiology)SmokingNeoplasms Second PrimaryMiddle AgedPrognosisVascular endothelial growth factorSurvival RateCarcinoma Squamous CellPeriodonticsBiomarker (medicine)FemaleMouth NeoplasmsOral SurgeryAdultmedicine.medical_specialtyGuanineGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideDisease-Free SurvivalPathology and Forensic MedicineCytosineYoung AdultInternal medicinemedicineCarcinomaHumansSurvival rateAgedNeoplasm StagingRetrospective Studiesbusiness.industryHaplotypemedicine.diseasestomatognathic diseasesOtorhinolaryngologychemistryHaplotypesNeoplasm Recurrence LocalbusinessThymineFollow-Up StudiesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct